Tumor angiogenic endothelial cells (TECs)

Tumor angiogenic endothelial cells (TECs) are a specialized population of endothelial cells that line the blood vessels within a tumor microenvironment. Unlike normal quiescent endothelial cells, TECs are characterized by rapid proliferation, increased migration, and significant structural abnormalities, such as gaps between cells and a lack of proper pericyte coverage (Hida et al., 2018, Cancer Science). These cells are driven by high levels of pro-angiogenic factors, most notably Vascular Endothelial Growth Factor (VEGF), which triggers the formation of new blood vessels to supply the growing tumor with oxygen and nutrients (Apte et al., 2019, Physiological Reviews). In oncology, TECs are a primary focus of anti-angiogenic therapy, where drugs aim to starve the tumor by inhibiting the signaling pathways that maintain these cells or by directly destroying the tumor vasculature. While TECs themselves are a cell type rather than a single molecular target, they express specific receptors and markers—such as VEGFR2, Tie2, and Endoglin—that serve as the actual therapeutic targets for monoclonal antibodies and small molecule inhibitors (Dudley, 2012, ACS Nano). Targeting these cells is a cornerstone of treatment for various solid tumors, although challenges such as acquired resistance and systemic toxicities like hypertension remain significant clinical hurdles.

Other names

Tumor endothelial cellsTumor-associated endothelial cellsTumor-derived endothelial cellsAngiogenic vascular endothelial cells

Inhibition of vascular endothelial growth factor (VEGF) signaling, inhibition of Tie2 signaling, disruption of established tumor vasculature (vascular disrupting agents), and inhibition of endothelial cell proliferation and migration.